A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Cell culture === Connecting the DMF chip to use in the field or world-to-chip interfaces have been accomplished by means of manual pumps and reservoirs which deliver microbes, cells, and media to the device. The lack of extensive pumps and valves allow for elaborate multi step applications involving cells performed in a simple and compact system. In one application, microbial cultures have been transferred onto the chip and allowed to grow with the use of sterile procedures and temperature required for microbial incubation. To validate that this was a viable space for microbial growth, a transformation assay was carried out in the device. This involves exposing E.coli to a vector and heat shocking the bacteria until they take up the DNA. This is then followed by running a DNA gel to assure that the wanted vector was taken up by the bacteria. This study found that the DNA indeed was taken up by the bacteria and expressed as predicted. Human cells have also been manipulated in Digital Microfluidic Immunocytochemistry in Single Cells (DISC) where DMF platforms were used to culture and use antibodies to label phosphorylated proteins in the cell. Cultured cells are then removed and taken off chip for screening. Another technique synthesizes hydrogels within DMF platforms. This process uses electrodes to deliver reagents to produce the hydrogel, and delivery of cell culture reagents for absorption into the gel. The hydrogels are an improvement over 2D cell culture because 3D cell culture have increased cell-cell interactions and cel-extracellular matrix interactions.
Women who became pregnant within approximately six months of the final dose showed vaccine efficacy estimates between 57% and 86% against parasitaemia in pregnancy. Because malaria and HIV infections frequently overlap geographically, PfSPZ Vaccine has been studied in HIV-positive adults. A randomized, double-blind, placebo-controlled trial in Tanzania administered five intravenous doses to HIV-negative and well-controlled HIV-positive participants. The vaccine was safe in both groups, but protection against CHMI was observed only in HIV-negative individuals, with an estimated vaccine efficacy of 80% in HIV-negative adults and no measurable efficacy in the HIV-positive cohort. Serological profiling indicated that HIV infection did not markedly diminish the magnitude of antibody responses to key sporozoite antigens, although cellular correlates of protection appear impaired in HIV-positive individuals. Recent analyses have examined the immune targets associated with PfSPZ-induced protection. Whole-proteome antibody profiling in Tanzanian trial participants revealed that vaccination elicits a focused IgG and IgM response to a limited set of Plasmodium falciparum antigens, including circumsporozoite protein and several liver- and blood-stage proteins. A whole-genome sieve analysis of parasites obtained from vaccinated and placebo recipients in West African field trials identified distinct parasite polymorphisms associated with vaccine breakthrough infections.
The UK provides the Operational Ration Pack, General Purpose. Packed inside a small cardboard box, each ration has enough retort-pouched and canned foods to feed one soldier for 24 hours. Seven menus (plus vegetarian and religious variants) provide two precooked meals (Breakfast and Main Meal) plus a midday snack. Example (Menu A) Breakfast: Hamburger and beans, Instant Porridge. All ration packs also contain Oatmeal Block, Fruit Biscuits, Biscuits Brown (a more compact alternative to bread), a sachet of instant soup and jam or yeast extract (a Marmite like spread) for a lunchtime snack, and chocolate (in the form of a specially made Yorkie bar which is flatter than civilian bars, or, more recently, a simple unbranded bar of milk chocolate), though this has been phased out with the introduction of the more recent multi-climate ration packs, and boiled sweets (hard candy) for snacking whilst on patrol, or in free time. Main Meal: Instant soup, Chicken with Mushroom and Pasta, Treacle Pudding. Each pack also contains instant coffee, tea bags, creamer, sugar, hot cocoa mix, beef/vegetable stock powder, lemon/orange powder or Lucozade electrolyte powder, matches, packet of tissues, chewing-gum, a small bottle of Tabasco sauce, and water purifying tablets. They sometimes also contain chicken and herb pâté. Also available are Kosher/Halal, Vegetarian, and Hindu/Sikh specific menus. Regardless of their contents, these ration packs are referred to as Rat-Packs or Compo (short for Composite Rations) by the soldiers who eat them.
Sources: en.wikipedia.org
== Education and military service == Beynon was born in the Welsh coal-mining town of Ystalyfera and was the older of two brothers. He went on to attend the University of Wales at Swansea (now Swansea University) in the early 1940s at the start of World War II.
The Rhizoplaca melanophthalma complex (rock-posy lichens) illustrates this complexity. Formerly treated as one circumpolar species with variable forms, the group is now recognized as several genetically distinct but partly hybridising species. Keuler and colleagues (2020) used genome-scale data and detected at least three historic hybridisation events. Network analysis showed that one lineage, Rhizoplaca shushanii, arose from hybridisation between R. melanophthalma and R. parilis and that low-level gene flow still occurs among some lineages. The hybrids lineages have unusual traits: R. shushanii is an alpine endemic with a distinct appearance, and two other lineages that were involved in introgression (gene flow between species) (R. haydenii and R. arbuscula) are vagrant forms that do not attach to rock but blow around on soil and reproduce only asexually. The study found discordance between nuclear and mitochondrial DNA trees (mitochondria from one species had introgressed into another), and the authors suggest that hybridization events might be linked to the loss of sexual reproduction and the evolution of these unusual, unattached growth forms. Systematically, the case shows that species boundaries can be porous and that reticulate evolution must be tested—single-locus barcodes can mislead when hybridisation is present. It also shows why relying on a single genetic locus (such as the ITS barcode alone) can be misleading: different genes in the same organisms have different histories if hybrids are involved.
The enzyme 2-dehydro-3-deoxy-phosphogluconate aldolase (EC 4.1.2.14), commonly known as KDPG aldolase, catalyzes the chemical reaction 2-dehydro-3-deoxy-D-gluconate 6-phosphate ⇌ {\displaystyle \rightleftharpoons } pyruvate + D-glyceraldehyde 3-phosphate This enzyme belongs to the family of lyases, specifically the aldehyde-lyases, which cleave carbon-carbon bonds. It is used in the Entner–Doudoroff pathway in prokaryotes, feeding into glycolysis. 2-dehydro-3-deoxy-phosphogluconate aldolase is one of the two enzymes distinguishing this pathway from the more commonly known Embden–Meyerhof–Parnas pathway. This enzyme also participates in following 3 metabolic pathways: pentose phosphate pathway, pentose and glucuronate interconversions, and arginine and proline metabolism. In addition to the cleavage of 2-dehydro-3-deoxy-D-gluconate 6-phosphate, it is also found to naturally catalyze Schiff base formation between a lysine ε-amino acid group and carbonyl compounds, decarboxylation of oxaloacetate, and exchange of solvent protons with the methyl hydrogen atoms of pyruvate.
== Uranium-230 == Uranium-230 is an artificial isotope of uranium with a half-life of 20.8 days. It has potential to be used in targeted alpha therapy. It is prepared from decay of protactinium-230, which is produced from proton irradiation of thorium targets.
Sources: en.wikipedia.org
Standard reuptake inhibitors are believed to act simply as competitive substrates that work by binding directly to the plasmalemma transporter of the neurotransmitter in question. They occupy the transporter in place of the respective neurotransmitter and competitively block it from being transported from the nerve terminal or synapse into the pre-synaptic neuron. With high enough doses, occupation becomes as much as 80–90%. At this level of inhibition, the transporter will be considerably less efficient at removing excess d from the synapse and this causes a substantial increase in the extracellular concentrations of the neurotransmitter and therefore an increase in overall neurotransmission.
== Special cases == Examples of tangential quadrilaterals are the kites, which include the rhombi, which in turn include the squares. The kites are exactly the tangential quadrilaterals that are also orthodiagonal. A right kite is a kite with a circumcircle. If a quadrilateral is both tangential and cyclic, it is called a bicentric quadrilateral, and if it is both tangential and a trapezoid, it is called a tangential trapezoid.
== Spy&Go affinity purification == Mutation of the catalytic glutamic acid residue (E77) in SpyCatcher to alanine stops isopeptide bond formation but does not prevent the initial non-covalent SpyTag/SpyCatcher association. This non-covalent SpyTag/SpyCatcher interaction has been utilized in the affinity purification of SpyTag-fused recombinant proteins. In this purification strategy, termed Spy&Go, resin-immobilized SpyCatcher is used to harvest SpyTag-fused proteins from cell culture supernatants or cell lysates. Non-specifically bound proteins are removed by washing the resin with a neutral buffer and the target protein eluted at neutral pH using high imidazole concentration. The Spy&Go affinity resin is based on SpyCatcher2.1 E77A S49C variant termed SpyDock. SpyDock can be expressed in E. coli as soluble protein, purified using Ni-NTA and anion-exchange resins and immobilized to iodoacetyl-activated agarose through the unpaired cysteine introduced by the S49C substitution. In neutral buffers with physiological salt concentration SpyDock binds to SpyTag- and SpyTag002-fused proteins with affinity in the high nanomolar range (Kd = 750 ± 50 nM for SpyTag, Kd = 73 ± 13 nM for SpyTag002). Affinity to SpyTag003 has not been reported, but requires harsher conditions to ensure full dissociation suggesting it binds tighter. SpyDock-bound proteins are eluted by incubating the resin with 2.5 M imidazole in neutral buffer. The SpyDock resin can be regenerated several times using consecutive washes with 4 M imidazole, 6 M guanidinium hydrochloride and 0.1 M NaOH.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.